70 Part III / Contemporary Treatment
30. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during
coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429–1435.
31. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody
against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet
1994;343:881–886.
32. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin dur-
ing percutaneous coronary revascularization. N Engl J Med 1997;336:1689–1696.
33. Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet gly-
coprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre ran-
domised trial. Lancet 1999;354:2019–2024.
34. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implanta-
tion (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037–2044.
35. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled
trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet
1998;352:87–92.
36. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis:
results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. Circulation 1999;99:2720–2732.
37. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease.
Circulation 2000;101:570–580.
38. Schultz RD, Heuser RR, Hatler C, et al. Use of c7E3 Fab in conjunction with primary coronary stent-
ing for acute myocardial infarctions complicated by cardiogenic shock. Cathet Cardiovasc Diagn
1996;39:143–148.
39. Giri S, Mitchel JF, Hirst JA, et al. Synergy between intracoronary stenting and abciximab in improving
angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction. Am J Car-
diol 2000;86:269–274.
40. Hasdai D, Kitt MM, Harrington RA, et al. Impact of platelet glycoprotein IIb/IIIa blockade on out-
come of cardiogenic shock among patients with acute coronary syndromes without persistent ST-seg-
ment elevation [abstract]. Circulation 1999;100(Suppl I):I-433.
41. LeDoux D, Astiz ME, Carpati CM, et al. Effects of perfusion pressure on tissue perfusion in septic
shock. Crit Care Med 2000;28:2792–2732.
42. Denton MD, Chertow GM, Brady HR. “Renal-dose” dopamine for the treatment of acute renal failure:
scientific rationale, experimental studies and clinical trials. Kidney Int 1996;50:4–14.
43. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Low-dose
dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Lancet
2000;356:2139–2143.
44. Juste RN, Moran L, Hooper J, et al. Dopamine clearance in critically ill patients. Intensive Care Med
1998;24:1217–1220.
45. Colucci WS, Denniss AR, Leatherman GF, et al. Intracoronary infusion of dobutamine to patients with
and without severe congestive heart failure: dose-response relationships, correlation with circulating
catecholamines, and effect of phosphodiesterase inhibition. J Clin Invest 1988;81:1103–1110.
46. Lowes BD, Simon MA, Tsvetkova TO, et al. Inotropes in the beta-blocker era. Clin Cardiol
2000;23(Suppl III):III-11–III-16.
47. Grose R, Strain J, Greenberg M, et al. Systemic and coronary effects of intravenous milrinone and
dobutamine in congestive heart failure. J Am Coll Cardiol 1986;7:1107–1113.
48. Menon V, Slater JN, White HD, et al. Acute myocardial infarction complicated by systemic hypoperfu-
sion without hypotension: report of the SHOCK Trial Registry. Am J Med 2000;108:374–380.
49. Hollenburg SM, Broussard M, Osman J, et al. Microvascular reactivity, blood pressure, and survival are
improved in septic iNOS-deficient knockout mice [abstract]. J Am Coll Cardiol 2000;35(Suppl A):312A.
50. Greenberg SS, Ouyang J, Zhao X. Inducible nitric oxide synthase mRNA and protein in ventricular
myocyte mitochondria in endotoxic shock [abstract]. Circulation 1998;98(Suppl I):I-132.
51. Cotter G, Kaluski E, Blatt A, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treat-
ment of cardiogenic shock [abstract]. Circulation 1999;100(Suppl I):I-371.
52. Cotter G, Kaluski E, Milovanov O, et al. LINCS: L-NMMA in cardiogenic shock: preliminary results
from a prospective randomized study. Presented at the American Heart Association Scientific Sessions
2001; Anaheim, California, USA; November 11–14, 2001.
53. Marzilli M, Orsini E, Marracini P, et al. Beneficial effects of intracoronary adenosine as an adjunct to
primary angioplasty in acute myocardial infarction. Circulation 2000;101:2154–2159.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196 |
Page 197 |
Page 198 |
Page 199 |
Page 200 |
Page 201 |
Page 202 |
Page 203 |
Page 204 |
Page 205 |
Page 206 |
Page 207 |
Page 208 |
Page 209 |
Page 210 |
Page 211 |
Page 212 |
Page 213 |
Page 214 |
Page 215 |
Page 216 |
Page 217 |
Page 218 |
Page 219 |
Page 220 |
Page 221 |
Page 222 |
Page 223 |
Page 224 |
Page 225 |
Page 226 |
Page 227 |
Page 228 |
Page 229 |
Page 230 |
Page 231 |
Page 232 |
Page 233 |
Page 234 |
Page 235 |
Page 236 |
Page 237 |
Page 238 |
Page 239 |
Page 240 |
Page 241 |
Page 242 |
Page 243 |
Page 244 |
Page 245 |
Page 246 |
Page 247 |
Page 248 |
Page 249 |
Page 250 |
Page 251 |
Page 252 |
Page 253 |
Page 254 |
Page 255 |
Page 256 |
Page 257 |
Page 258 |
Page 259 |
Page 260 |
Page 261 |
Page 262 |
Page 263 |
Page 264 |
Page 265 |
Page 266 |
Page 267 |
Page 268 |
Page 269 |
Page 270 |
Page 271 |
Page 272 |
Page 273 |
Page 274 |
Page 275 |
Page 276 |
Page 277 |
Page 278 |
Page 279 |
Page 280 |
Page 281 |
Page 282 |
Page 283 |
Page 284 |
Page 285 |
Page 286 |
Page 287 |
Page 288 |
Page 289 |
Page 290 |
Page 291 |
Page 292 |
Page 293 |
Page 294 |
Page 295 |
Page 296 |
Page 297 |
Page 298 |
Page 299 |
Page 300 |
Page 301 |
Page 302 |
Page 303 |
Page 304 |
Page 305 |
Page 306 |
Page 307 |
Page 308 |
Page 309 |
Page 310 |
Page 311 |
Page 312 |
Page 313 |
Page 314 |
Page 315 |
Page 316 |
Page 317 |
Page 318 |
Page 319 |
Page 320 |
Page 321 |
Page 322 |
Page 323 |
Page 324 |
Page 325 |
Page 326 |
Page 327 |
Page 328 |
Page 329 |
Page 330 |
Page 331 |
Page 332 |
Page 333 |
Page 334 |
Page 335 |
Page 336 |
Page 337 |
Page 338 |
Page 339 |
Page 340 |
Page 341 |
Page 342 |
Page 343 |
Page 344 |
Page 345 |
Page 346 |
Page 347 |
Page 348 |
Page 349 |
Page 350 |
Page 351 |
Page 352 |
Page 353 |
Page 354 |
Page 355 |
Page 356 |
Page 357 |
Page 358 |
Page 359 |
Page 360 |
Page 361 |
Page 362 |
Page 363 |
Page 364 |
Page 365 |
Page 366 |
Page 367 |
Page 368 |
Page 369 |
Page 370 |
Page 371 |
Page 372 |
Page 373 |
Page 374 |
Page 375 |
Page 376 |
Page 377 |
Page 378 |
Page 379 |
Page 380 |
Page 381 |
Page 382 |
Page 383 |
Page 384 |
Page 385 |
Page 386 |
Page 387 |
Page 388 |
Page 389 |
Page 390 |
Page 391 |
Page 392 |
Page 393